Sanofi

YTD

ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories.

CEO

Belén Garijo López

CEOBelén Garijo López

Employees

76,493

Employees76,493

Headquarters

Paris, Ile-de-France

HeadquartersParis, Ile-de-France

Founded

1994

Founded1994

Employees

76,493

Employees76,493

SNY Key Statistics

Market cap

111.41B

Market cap111.41B

Price-Earnings ratio

18.38

Price-Earnings ratio18.38

Dividend yield

3.99%

Dividend yield3.99%

Average volume

3.14M

Average volume3.14M

High today

$45.67

High today$45.67

Low today

$45.21

Low today$45.21

Open price

$45.44

Open price$45.44

Volume

1.10M

Volume1.10M

52 Week high

$52.68

52 Week high$52.68

52 Week low

$40.89

52 Week low$40.89

SNY News

TipRanks 12m

Sanofi’s MenQuadfi Safety Study in Korea: What Investors Should Watch

Sanofi SA (SNY) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inve...

TipRanks 13m

Sanofi’s Sarclisa Real‑World Data: What the Latest Multiple Myeloma Update Means for Investors

Sanofi (SNYNF) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inves...

Nasdaq 14h

The Smartest Dividend Stock to Buy With $1,000 Right Now (Spoiler: It Yields 5.6%.)

Key Points Sanofi is growing well, thanks in large part to its drug Dupixent. It has more drugs in development, some of which could turn into big sellers. It...

Analyst ratings

50%

of 8 ratings

Buy

50%

Hold

50%

Sell

More SNY News

TipRanks 2d

Malin Writes Down Kymab Contingent Value as Sanofi Halts Amlitelimab

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

TipRanks 2d

Sanofi Reshapes Executive Committee for Next Strategic Chapter

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Benzinga 5d

Sanofi Drops Dupixent Successor Candidate After Assessing Data

Two additional phase 3 studies, AQUA and ESTUARY, were anticipated to report results in the second half of 2026. Global regulatory submissions were planned for...

TipRanks 5d

Sanofi Advances Real-World Asthma Study, Sharpening Its Long-Term Biologics Strategy

Sanofi SA (SNY) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inve...

The Wall Street Journal 5d

Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO

Sanofi said midstage study of amlitelimab in celiac disease is under way, with results expected in the second half of the year. Gonzalo Fuentes / Reuters Sanof...

TipRanks 5d

Sanofi ends amLitelimab program in atopic dermatitis amid portfolio review

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.